Designing a First-in-Human Sequential Single-Dose Study of an Intrathecal Antisense Oligonucleotide in Adults with a Rare Genetic Neurological Disease: Starting-Dose Logic, Cerebrospinal Fluid Sampling, and Phase 1 Protocol Synopsis

An antisense oligonucleotide given into the cerebrospinal fluid reaches the nervous system directly, which changes the first-in-human problem: dose is a total amount in a small compartment, the route itself carries risk, and the earliest evidence of activity comes from a biomarker measured in spinal fluid. This article develops a hypothetical Phase 1 open-label, sentinel-led, sequential single-dose study of an intrathecal oligonucleotide that lowers an astrocyte structural protein in adults with a rare genetic neurological disease caused by a gain-of-function variant. It derives a 5 mg starting dose from assumed exposure modeling, escalates through 5, 10, and 25 mg in three cohorts of three to six participants under 3+3 rules with a 28-day dose-limiting toxicity window, and follows participants to Day 85. The synopsis specifies plasma and cerebrospinal fluid pharmacokinetic and biomarker sampling, lumbar-puncture safety rules, pharmacovigilance timelines, and a descriptive analysis for 9 to 18 participants. It explains why healthy volunteers are not used and why conventional dose scaling must be adapted for a local central nervous system route. All values are illustrative assumptions.Keywords: first-in-human; antisense oligonucleotide; intrathecal; cerebrospinal fluid; target engagement; sentinel dosing; Phase 1 protocol; rare disease

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24426632
Primary Topic
Statistical Methods in Clinical Trials
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Designing a First-in-Human Sequential Single-Dose Study of an Intrathecal Antisense Oligonucleotide in Adults with a Rare Genetic Neurological Disease: Starting-Dose Logic, Cerebrospinal Fluid Sampling, and Phase 1 Protocol Synopsis

Peivand Pirouzi, Junyi Wu, Atchaya Ravichandran
Zenodo (CERN European Organization for Nuclear Research)
Statistical Methods in Clinical Trials
article

Designing a First-in-Human Sequential Single-Dose Study of an Intrathecal Antisense Oligonucleotide in Adults with a Rare Genetic Neurological Disease: Starting-Dose Logic, Cerebrospinal Fluid Sampling, and Phase 1 Protocol Synopsis

Peivand Pirouzi, Junyi Wu, Atchaya Ravichandran
article en

Abstract

An antisense oligonucleotide given into the cerebrospinal fluid reaches the nervous system directly, which changes the first-in-human problem: dose is a total amount in a small compartment, the route itself carries risk, and the earliest evidence of activity comes from a biomarker measured in spinal fluid. This article develops a hypothetical Phase 1 open-label, sentinel-led, sequential single-dose study of an intrathecal oligonucleotide that lowers an astrocyte structural protein in adults with a rare genetic neurological disease caused by a gain-of-function variant. It derives a 5 mg starting dose from assumed exposure modeling, escalates through 5, 10, and 25 mg in three cohorts of three to six participants under 3+3 rules with a 28-day dose-limiting toxicity window, and follows participants to Day 85. The synopsis specifies plasma and cerebrospinal fluid pharmacokinetic and biomarker sampling, lumbar-puncture safety rules, pharmacovigilance timelines, and a descriptive analysis for 9 to 18 participants. It explains why healthy volunteers are not used and why conventional dose scaling must be adapted for a local central nervous system route. All values are illustrative assumptions.Keywords: first-in-human; antisense oligonucleotide; intrathecal; cerebrospinal fluid; target engagement; sentinel dosing; Phase 1 protocol; rare disease

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Statistical Methods in Clinical Trials
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon